MedTrace Logo

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-11-17

No results posted yet for this study

Summary

The premise of this study is that enteral tranexamic acid will help to maintain small bowel integrity, which is often compromised by critical illness due to inadequate cardiovascular perfusion (i.e., shock), and that maintenance of small bowel integrity will decrease morbidity in critically ill patients.

Conditions

Interventions

DRUG

Tranexamic Acid

DRUG

Control Intervention (Carrier fluid only)

Sponsors & Collaborators

  • Inflammagen/Leading Ventures

    collaborator UNKNOWN

  • San Diego Veterans Healthcare System

    lead FED

Principal Investigators

  • Erik B Kistler, MD, PhD · VA San Diego Healthcare/University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683747 on ClinicalTrials.gov